231 related articles for article (PubMed ID: 21595295)
41. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
42. Frosted branch angiitis and cerebral venous sinus thrombosis as an initial onset of neuro-Behçet's disease: a case report and review of the literature.
Ferreira BFA; Rodriguez EEC; Prado LLD; Gonçalves CR; Hirata CE; Yamamoto JH
J Med Case Rep; 2017 Apr; 11(1):104. PubMed ID: 28410605
[TBL] [Abstract][Full Text] [Related]
43. Infliximab for patients with neuro-Behcet's disease: case series and literature review.
Borhani Haghighi A; Safari A; Nazarinia MA; Habibagahi Z; Shenavandeh S
Clin Rheumatol; 2011 Jul; 30(7):1007-12. PubMed ID: 21431864
[TBL] [Abstract][Full Text] [Related]
44. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
45. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
46. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
47. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
48. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
Yalcin Kehribar D; Gunaydin S; Ozgen M
Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
50. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
51. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
52. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
53. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
[No Abstract] [Full Text] [Related]
55. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial.
Al-Rayes H; Al-Swailem R; Al-Balawi M; Al-Dohayan N; Al-Zaidi S; Tariq M
Rheumatol Int; 2008 Nov; 29(1):53-7. PubMed ID: 18496694
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
[TBL] [Abstract][Full Text] [Related]
58. [Low-dose weekly methotrexate therapy for progressive neuro-Behçet's disease].
Suda H
Nihon Rinsho Meneki Gakkai Kaishi; 1999 Feb; 22(1):13-22. PubMed ID: 11185687
[TBL] [Abstract][Full Text] [Related]
59. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
[TBL] [Abstract][Full Text] [Related]
60. New approaches in the treatment of Adamantiades-Behçet's disease.
Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C
Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
